FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149074758> ?p ?o ?g. }

• W2149074758 abstract "In dystrophin-deficient muscles of Duchenne Muscular Dystrophy (DMD) patients and the mdx mouse model, nitric oxide (NO) signalling is impaired. Previous studies have shown that NO-donating drugs are beneficial in dystrophic mouse models. Recently, a long-term treatment (9 months) of mdx mice with naproxcinod, an NO-donating naproxen, has shown a significant improvement of the dystrophic phenotype with beneficial effects present throughout the disease progression. It remains however to be clearly dissected out which specific effects are due to the NO component compared with the anti-inflammatory activity associated with naproxen. Understanding the contribution of NO vs the anti-inflammatory effect is important, in view of the potential therapeutic perspective, and this is the final aim of this study. Five-week-old mdx mice received either naproxcinod (30 mg/kg) or the equimolar dose of naproxen (20 mg/kg) in the diet for 6 months. Control mdx mice were used as reference. Treatments (or vehicle for control groups) were administered daily in the diet. For the first 3 months the study was performed in sedentary animals, then all mice were subjected to exercise until the sixth month. Skeletal muscle force was assessed by measuring whole body tension in sedentary animals as well as in exercised mice and resistance to fatigue was measured after 3 months of running exercise. At the end of 6 months of treatment, animals were sacrificed for histological analysis and measurement of naproxen levels in blood and skeletal muscle. Naproxcinod significantly ameliorated skeletal muscle force and resistance to fatigue in sedentary as well as in exercised mice, reduced inflammatory infiltrates and fibrosis deposition in both cardiac and diaphragm muscles. Conversely, the equimolar dose of naproxen showed no effects on fibrosis and improved muscle function only in sedentary mice, while the beneficial effects in exercised mice were lost demonstrating a limited and short-term effect. In conclusion, this study shows that NO donation may have an important role, in addition to anti-inflammatory activity, in slowing down the progression of the disease in the mdx mouse model therefore positioning naproxcinod as a promising candidate for treatment of DMD." @default.
• W2149074758 created "2016-06-24" @default.
• W2149074758 creator A5000350455 @default.
• W2149074758 creator A5004535372 @default.
• W2149074758 creator A5007995825 @default.
• W2149074758 creator A5010848776 @default.
• W2149074758 creator A5037364050 @default.
• W2149074758 creator A5043885870 @default.
• W2149074758 creator A5052576774 @default.
• W2149074758 creator A5085140427 @default.
• W2149074758 date "2015-08-22" @default.
• W2149074758 modified "2023-09-27" @default.
• W2149074758 title "Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy" @default.
• W2149074758 cites W102817091 @default.
• W2149074758 cites W1508659364 @default.
• W2149074758 cites W1514670900 @default.
• W2149074758 cites W1522411479 @default.
• W2149074758 cites W1547864103 @default.
• W2149074758 cites W1601005193 @default.
• W2149074758 cites W1681560813 @default.
• W2149074758 cites W1957992664 @default.
• W2149074758 cites W1968854849 @default.
• W2149074758 cites W1985183676 @default.
• W2149074758 cites W1988999122 @default.
• W2149074758 cites W1990433203 @default.
• W2149074758 cites W1994257334 @default.
• W2149074758 cites W2003414258 @default.
• W2149074758 cites W2005402291 @default.
• W2149074758 cites W2007146615 @default.
• W2149074758 cites W2008980136 @default.
• W2149074758 cites W2010685234 @default.
• W2149074758 cites W2016969982 @default.
• W2149074758 cites W2017056887 @default.
• W2149074758 cites W2019729102 @default.
• W2149074758 cites W2020685420 @default.
• W2149074758 cites W2022325044 @default.
• W2149074758 cites W2023869046 @default.
• W2149074758 cites W2033676880 @default.
• W2149074758 cites W2035841380 @default.
• W2149074758 cites W2042054187 @default.
• W2149074758 cites W2046943947 @default.
• W2149074758 cites W2049356816 @default.
• W2149074758 cites W2051741101 @default.
• W2149074758 cites W2052928078 @default.
• W2149074758 cites W2059155059 @default.
• W2149074758 cites W2066180106 @default.
• W2149074758 cites W2067161820 @default.
• W2149074758 cites W2070549532 @default.
• W2149074758 cites W2071721339 @default.
• W2149074758 cites W2076670842 @default.
• W2149074758 cites W2095157830 @default.
• W2149074758 cites W2099696378 @default.
• W2149074758 cites W2102009945 @default.
• W2149074758 cites W2102866954 @default.
• W2149074758 cites W2103017013 @default.
• W2149074758 cites W2103468284 @default.
• W2149074758 cites W2103597137 @default.
• W2149074758 cites W2105011888 @default.
• W2149074758 cites W2109987159 @default.
• W2149074758 cites W2116403540 @default.
• W2149074758 cites W2126403177 @default.
• W2149074758 cites W2126792732 @default.
• W2149074758 cites W2131396113 @default.
• W2149074758 cites W2138040672 @default.
• W2149074758 cites W2148132280 @default.
• W2149074758 cites W2153347240 @default.
• W2149074758 cites W2154720746 @default.
• W2149074758 cites W2156028141 @default.
• W2149074758 cites W2160269980 @default.
• W2149074758 cites W2160600666 @default.
• W2149074758 cites W2164481873 @default.
• W2149074758 cites W2166018242 @default.
• W2149074758 cites W2167330344 @default.
• W2149074758 cites W2168984459 @default.
• W2149074758 cites W2170628647 @default.
• W2149074758 cites W4243662287 @default.
• W2149074758 doi "https://doi.org/10.1186/s13023-015-0311-0" @default.
• W2149074758 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4546261" @default.
• W2149074758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26296873" @default.
• W2149074758 hasPublicationYear "2015" @default.
• W2149074758 type Work @default.
• W2149074758 sameAs 2149074758 @default.
• W2149074758 citedByCount "12" @default.
• W2149074758 countsByYear W21490747582016 @default.
• W2149074758 countsByYear W21490747582017 @default.
• W2149074758 countsByYear W21490747582018 @default.
• W2149074758 countsByYear W21490747582019 @default.
• W2149074758 countsByYear W21490747582020 @default.
• W2149074758 countsByYear W21490747582021 @default.
• W2149074758 countsByYear W21490747582023 @default.
• W2149074758 crossrefType "journal-article" @default.
• W2149074758 hasAuthorship W2149074758A5000350455 @default.
• W2149074758 hasAuthorship W2149074758A5004535372 @default.
• W2149074758 hasAuthorship W2149074758A5007995825 @default.
• W2149074758 hasAuthorship W2149074758A5010848776 @default.
• W2149074758 hasAuthorship W2149074758A5037364050 @default.
• W2149074758 hasAuthorship W2149074758A5043885870 @default.
• W2149074758 hasAuthorship W2149074758A5052576774 @default.
• W2149074758 hasAuthorship W2149074758A5085140427 @default.
• W2149074758 hasBestOaLocation W21490747581 @default.

• next